Short answer: Mounjaro is a diabetes medicine. Its label covers blood sugar control in type 2 diabetes and, in the current label revised August 2026, cardiovascular risk reduction in high-risk adults with type 2 diabetes. Weight loss shows up in its trials as a secondary effect, but weight management is Zepbound's label, not Mounjaro's.
| Question | Label answer |
|---|---|
| Who it is for | Adults and children 10 years and older with type 2 diabetes, with diet and exercise |
| Second indication | Reduce the risk of cardiovascular death, heart attack or stroke in adults with type 2 diabetes at high risk for these events |
| Starting dose | 2.5 mg once weekly |
| Increases | 2.5 mg steps, at least 4 weeks apart, if more glucose control is needed |
| Maximum | 15 mg weekly (adults); 10 mg weekly (children) |
| Forms | Single-dose pen, single-dose vial, multi-dose vial, KwikPen |
| First approved | May 13, 2022 (Drugs@FDA) |
Who is Mounjaro approved for?
Mounjaro is approved for people with type 2 diabetes. The label lets prescribers use it to improve glycemic control in adults and in children 10 years and older.
The current label, revised August 2026, adds a second use: lowering the risk of major adverse cardiovascular events in adults with type 2 diabetes who are at high risk for them. Mounjaro has no indication for people without diabetes. The label's GLP-1 basics are explained in GLP-1 drugs and type 2 diabetes.
How is Mounjaro dosed?
Everyone starts at 2.5 mg once a week. If more blood sugar control is needed, the dose goes up by 2.5 mg after at least 4 weeks on the current dose.
Adults can reach 15 mg weekly; children are capped at 10 mg. Missed doses can be taken within 4 days (96 hours), and the injection day can move as long as doses stay at least 3 days apart. Mounjaro can lower blood sugar too far when combined with insulin or a sulfonylurea, so prescribers may adjust those drugs. Follow your prescriber's plan rather than any generic schedule.
What did the SURPASS trials show?
In the label's trials, Mounjaro lowered HbA1c by roughly 1.7 to 2.3 percentage points, depending on the trial and dose. The table pulls the figures straight from the label.
| Trial | Comparison | Length | Main result |
|---|---|---|---|
| SURPASS-1 | 5, 10, 15 mg vs placebo, no other diabetes drugs (478 adults) | 40 weeks | HbA1c fell 1.7 to 1.8 points vs 0.1 on placebo |
| SURPASS-2 | 5, 10, 15 mg vs semaglutide 1 mg, added to metformin (1,879 adults) | 40 weeks | HbA1c fell 2.0, 2.2 and 2.3 points vs 1.9; weight fell 7.6, 9.3 and 11.2 kg vs 5.7 kg |
| SURPASS-PEDS | 5 and 10 mg vs placebo, ages 10 and up (99 patients) | 30 weeks | Statistically significant HbA1c reduction vs placebo |
| SURPASS-CVOT | Up to 15 mg vs dulaglutide 1.5 mg (13,299 adults with heart disease) | Median 210.1 weeks | Non-inferior for heart attack, stroke or CV death: hazard ratio 0.92 (95.3% CI 0.83 to 1.01); superiority not shown |
SURPASS-CVOT is worth reading carefully. It compared Mounjaro with another active drug, Trulicity, not with placebo, and it showed Mounjaro was not worse. It did not prove Mounjaro was better. Our dulaglutide guide covers the comparator.
Why isn't Mounjaro labeled for weight loss?
Because the trials behind Mounjaro were diabetes trials, and FDA approves uses based on the studies submitted. Lilly ran separate weight-management trials, SURMOUNT, and those supported a separate brand, Zepbound, approved in November 2023.
The weight change in SURPASS-2 was measured as a secondary outcome in people with diabetes. That is different from an approved weight indication. In practice, the split matters most for insurance: plans that cover diabetes drugs often exclude weight-management drugs, and claims are usually checked against the diagnosis. See Mounjaro vs Zepbound for the side-by-side.
How much does Mounjaro cost without insurance?
We could not read Lilly's own Mounjaro list price: Lilly's pricing page returned an error on November 8, 2026. What we have are telehealth providers' printed prices, which are not manufacturer prices.
- Mochi Health listed brand Mounjaro "as low as" $499 at the 2.5 mg dose, read October 15, 2026. Mochi's membership is billed separately.
- Hims & Hers listed Mounjaro pens at $1,899 a month, read September 17, 2026, with medication billed separately from its membership.
As arithmetic only, 12 months at Mochi's $499 floor would be $5,988 before membership, and higher doses may cost more. If you have type 2 diabetes and insurance, your plan's formulary price will usually matter far more than any cash price.
Is Walmart covering Mounjaro in 2027?
CNBC reported on October 13, 2026 that Walmart will offer Mounjaro and Ozempic at no cost to employees with type 2 diabetes in 2027, after a new prior authorization, as part of more than 250 no-cost prescriptions. The same report said Walmart still does not cover GLP-1s for weight loss.
That is a news report, not a Walmart plan document. We did not read Walmart's 2027 benefits materials, so check your own plan summary for the exact rules.
What safety warnings does Mounjaro carry?
The label has a boxed warning about thyroid C-cell tumors seen in rats, and Mounjaro must not be used by people with a personal or family history of medullary thyroid carcinoma or with MEN 2. Other label warnings cover pancreatitis, low blood sugar with insulin or sulfonylureas, allergic reactions, kidney injury from dehydration, severe stomach and bowel effects, diabetic eye complications, gallbladder disease and aspiration under anesthesia.
The KwikPen should never be shared between people. For how tirzepatide works and how it compares with semaglutide, read the tirzepatide guide.
Frequently asked questions
Can a doctor prescribe Mounjaro for weight loss?
Mounjaro's FDA label covers type 2 diabetes, not weight management. Using a drug outside its label is a prescriber's decision, but insurers commonly deny Mounjaro claims without a type 2 diabetes diagnosis. For weight management, FDA approved the same molecule under the Zepbound brand, which has its own label, dosing for that use and self-pay program.
Is Mounjaro approved for children?
Yes, for type 2 diabetes. The label revised August 2026 covers glycemic control in children 10 years and older, based on the 30-week SURPASS-PEDS trial in 99 patients. The maximum pediatric dose is 10 mg weekly, and the label says the KwikPen is not recommended for self-injection by children. The cardiovascular indication applies to adults only.
Did Mounjaro beat Trulicity for heart outcomes?
Not statistically. In SURPASS-CVOT, 13,299 adults with type 2 diabetes and heart disease received Mounjaro up to 15 mg or Trulicity 1.5 mg for a median 210.1 weeks. The hazard ratio for heart attack, stroke or cardiovascular death was 0.92, with a confidence interval reaching 1.01. Mounjaro was shown non-inferior, and superiority was not established.
What is the Mounjaro starting dose?
The label starts everyone at 2.5 mg injected once a week. If blood sugar needs more control, the dose rises in 2.5 mg steps with at least 4 weeks between increases, up to 15 mg for adults or 10 mg for children. Your prescriber decides whether to increase, and may lower insulin or sulfonylurea doses at the same time.
How did Mounjaro compare with semaglutide in SURPASS-2?
In SURPASS-2, adults on metformin received Mounjaro 5, 10 or 15 mg or semaglutide 1 mg for 40 weeks. HbA1c fell 2.0, 2.2 and 2.3 points on Mounjaro versus 1.9 on semaglutide, and body weight fell 7.6 to 11.2 kg versus 5.7 kg, per the label. The trial used semaglutide's 1 mg diabetes dose, not the higher weight-management doses.
Sources
- FDA label (DailyMed): Mounjaro prescribing information — label revised August 2026 (SPL effective August 27, 2026); sections 1, 2, 3, 5, 14 read 2026-11-08
- Drugs@FDA: Mounjaro (NDA 215866) — original approval May 13, 2022; queried 2026-11-08
- CNBC: Walmart employee benefits add no-cost GLP-1s in 2027 — news report published October 13, 2026; read 2026-11-08; not a Walmart plan document
- Mochi Health: per-dose pricing (brand 'as low as' prices) — provider page read 2026-10-15
- Hims & Hers: weight loss pricing — read 2026-09-17; re-read blocked 2026-10-15
- Lilly: Mounjaro pricing information — returned HTTP 403 on 2026-11-08; no list price used
Comparing programs? Check the all-in monthly price, the named pharmacy and the cancellation terms on the provider's own page before you pay.
Check NexLife's plans and state availability → See the price index